Equity Profile

ARWR

Arrowhead Pharmaceuticals, Inc.

Health CareBiotechnology$12.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ3-2026After Close5:00 PM EDT

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious diseases using its proprietary RNA interference technology....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-1.49

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

64M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious diseases using its proprietary RNA interference technology. With a market cap of $12 billion, the company plays a significant role in the healthcare sector, particularly in innovative drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q2-2026, Arrowhead reported an EPS of -$0.93, which was better than the expected -$1.18, surprising analysts positively. However, revenue details were not disclosed, and the stock price fell by 1.50% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are anticipating a challenging quarter for Arrowhead, with a consensus EPS of -$1.49 and revenue expectations of $64 million. The market is closely watching how the company performs against these estimates.

Bull Case

If Arrowhead can beat EPS expectations and show strong revenue growth, it could signal a positive turnaround and renewed investor confidence in its product pipeline.

Bear Case

Conversely, if the company misses its EPS and revenue targets, it may raise concerns about its financial stability and future growth prospects, leading to further stock declines.

Key Metrics to Watch

EPS

-1.49

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

64M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Arrowhead meet or exceed the consensus EPS estimate of -$1.49?

This figure will be crucial for assessing the company's profitability and could significantly influence investor sentiment.

What revenue figures will Arrowhead report, and how do they compare to the $64 million consensus?

Revenue performance will provide insights into market demand and the effectiveness of Arrowhead's product strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating Arrowhead's potential for a surprise in revenue due to recent advancements in its product pipeline that have not been fully factored into analyst models.

Supporting Evidence

The company has historically shown volatility in earnings, with significant surprises in past quarters.

Options pricing suggests a larger move than historical averages, indicating that traders expect more volatility than the consensus reflects.

Key Risk

If Arrowhead's revenue exceeds $64 million, it could shift the narrative and lead to a reevaluation of its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Arrowhead's ability to turn around its financial performance amidst ongoing challenges in the biotech sector.

Bull Confirmed If

A reported EPS better than -$1.49 and revenue exceeding $64 million would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.49 and revenue below $64 million would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty around the earnings report.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations, history suggests a potential stock increase of around 2.86%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on future guidance.

Miss

A miss on earnings could lead to a decline of approximately 0.17%, reflecting investor disappointment and concerns over the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of Arrowhead's key drug candidates and their expected timelines.
2Insights into the company's strategy for addressing market competition.
3Management's commentary on operational challenges and how they plan to overcome them.
4Details on any partnerships or collaborations that could impact future revenue.
5Future guidance on expected revenue and EPS for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious diseases using its proprietary RNA interference technology....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-1.49

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

64M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Arrowhead can beat EPS expectations and show strong revenue growth, it could signal a positive turnaround and renewed investor confidence in its product pipeline.

Bear Case

Conversely, if the company misses its EPS and revenue targets, it may raise concerns about its financial stability and future growth prospects, leading to further stock declines.

Key Metrics to Watch

EPS

-1.49

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

64M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Arrowhead meet or exceed the consensus EPS estimate of -$1.49?

This figure will be crucial for assessing the company's profitability and could significantly influence investor sentiment.

What revenue figures will Arrowhead report, and how do they compare to the $64 million consensus?

Revenue performance will provide insights into market demand and the effectiveness of Arrowhead's product strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating Arrowhead's potential for a surprise in revenue due to recent advancements in its product pipeline that have not been fully factored into analyst models.

Supporting Evidence

The company has historically shown volatility in earnings, with significant surprises in past quarters.

Options pricing suggests a larger move than historical averages, indicating that traders expect more volatility than the consensus reflects.

Key Risk

If Arrowhead's revenue exceeds $64 million, it could shift the narrative and lead to a reevaluation of its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Arrowhead's ability to turn around its financial performance amidst ongoing challenges in the biotech sector.

Bull Confirmed If

A reported EPS better than -$1.49 and revenue exceeding $64 million would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.49 and revenue below $64 million would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating high uncertainty around the earnings report.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations, history suggests a potential stock increase of around 2.86%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity on future guidance.

Miss

A miss on earnings could lead to a decline of approximately 0.17%, reflecting investor disappointment and concerns over the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of Arrowhead's key drug candidates and their expected timelines.
2Insights into the company's strategy for addressing market competition.
3Management's commentary on operational challenges and how they plan to overcome them.
4Details on any partnerships or collaborations that could impact future revenue.
5Future guidance on expected revenue and EPS for the next quarter.